Veradigm discloses ICFR weakness related to rev rec software tool
By Adrianne Appel2023-03-23T18:56:00
Healthcare technology company Veradigm disclosed it expects it misstated revenue by approximately $40 million during its 2021 and 2022 reporting periods.
Veradigm previously disclosed it misstated revenues going back to the third quarter of 2021 by $20 million, but an expanded audit discovered additional problems leading to the updated total, the company stated in a regulatory filing with the Securities and Exchange Commission (SEC) on Wednesday.
The company said its quarterly reports and year-end reports from March 2021 through September 2022 should not be relied on. The misstatements were made because of internal control over financial reporting (ICFR) deficiencies, the company said.